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We previously reported that, when the colon 26 murine colon
carcinoma is inoculated into mice subcutaneously (s.c.), it causes
progressive body weight loss, adipose tissue and muscle wasting,
and other homeostasis disorders associated with cachexia (Tanaka
et al, 1990). Cachexia is known to be caused by mediators
produced by tumours or by the host as a result of tumour–host
interaction. Previously, various factors have been proposed as
cachexia mediators, such as tumour necrosis factor alpha (TNF-a)
(Oliff et al, 1987; Tracey et al, 1988; Stovroff et al, 1988; Yoneda
et al, 1991), interferon gamma (IFN-g) (Matthys et al, 1991a,
1991b), interleukin (IL)-1a (Moldawer et al, 1987; Gelin et al,
1991), leukaemia inhibitory factor (LIF) (Mori et al, 1991) and IL-
6 (Yoneda et al, 1993; Tamura et al, 1995). Fujimoto-Ouchi et al
(1995) and Strassmann et al (1992a) reported that anti-IL-6 anti-
body suppressed the progressive body weight loss and other disor-
ders associated with cachexia in mice bearing colon 26. It is
therefore likely that IL-6 would be one of the cachexia mediators
in the colon 26 model.
During our studies on cachexia in the colon 26 model, we
discovered that tumour cells inoculated into the liver lost the
ability to induce progressive weight loss, even though the same
tumour cells inoculated into the subcutis or the muscle cause
cachexia. Cancer cells often cause phenotypic changes even in
vivo that are dependent upon the environment in which these cells
are growing. Cachexia may be one such phenotype, the expression
of which is dependent on that particular environment. The present
study demonstrates that different cachexia phenotypes are
produced by the same colon 26 cells when they are growing in
different environments, subcutaneously (s.c.) and in the liver. In
addition, we investigated such aspects of the tumour grown in the
different environments as its IL-6 productivity and histological
characteristics. Results from the present study suggest that
cachexia in mice bearing colon 26 would be induced only in an
environment where IL-6 is produced.
MATERIALS AND METHODS
Mice
Male 4-week-old BALB/c ´ DBA/2 F1 mice were obtained from
SLC (Hamamatsu, Japan); they were used for experiments after
being acclimated for 1 week. The animal house is kept at 24 ± 2°C
with a 12-h dark–light cycle. The mice were fed with breeding diet
F1 (Funabashi Farm, Funabashi, Japan), containing 21.3% protein,
57.1% carbohydrates, 5.6% fat, 3.3% fibre, 5.7% ash and 7.0%
moisture (metabolic calories, 3.76 kcal/g), and given water ad
libitum. All studies were conducted in accordance with ‘the
Guidelines for the Care and Use of Laboratory Animals in Nippon
Roche Research Center’.
Tumour
A subclone of colon 26, clone 20 which causes progressive weight
loss (Fujimoto-Ouchi et al, 1995), was used in the study. Colon 26
cells were maintained in vitro with Roswell Park Memorial
Institute (RPMI)-1640 containing 10% fetal bovine serum in a
humidified atmosphere with 5% carbon dioxide at 37°C. The cells
were treated with 0.05% trypsin and 0.02% EDTA to obtain a
single cell suspension and then inoculated into the liver (1 ´ 104
cells) via a branch of the jejunal veins for one group of mice,
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Summary Murine colon 26 carcinoma growing at either subcutaneous (s.c.) or intramuscular (i.m.) inoculation sites causes cachexia in mice.
Such animals show extensive loss of body weight, wasting of the muscle and adipose tissues, hypoglycaemia, and hypercalcaemia, even
when the tumour weight comprises only about 1.9% of carcass weight. In contrast, the same tumour when inoculated into the liver does not
cause any sign of tumour-related cachexia even when the tumour becomes much larger (6.6% of carcass weight). Interleukin 6 (IL-6), a
mediator associated with cachexia in this tumour model, is detected at high levels both in the tumour tissues and in the circulating blood of
mice bearing colon 26 tumour at the s.c. inoculation site. In contrast, only minute levels of IL-6 are detected in the tumour grown in the liver.
The colon 26 tumour grown in the liver does not lose its ability to cause cachexia, because the tumour when re-inoculated s.c. is able to cause
extensive weight loss and produce IL-6 as did the original colon 26 cell line. Histological studies revealed differences in the composition of
tumour tissues: the tumours grown in the subcutis consist of many polygonal tumour cells, extended-intercellular space, and high vascular
density, whereas those grown in the liver consist of spindle-shaped tumour cells. Thus, the environment where tumour cells grow would be a
critical factor in determining the cachectic phenotype of cancer cells, including their ability to produce IL-6.
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247-0063, Japanwhich were anaesthetized with pentobarbital sodium at 100 mg/kg
intraperitoneally (i.p.). In the other group of mice, colon 26 cells (5
´ 105 cells) were inoculated into the subcutis of the right flank
after a sham operation to reveal the jejunal vein. In some experi-
ments, the colon 26 grown in the liver was cut into an approxi-
mately 8-mm3 piece of tumour block and was re-transplanted s.c.
into mice by means of a trocar. Another group of mice that were
inoculated with colon 26 cells (5 ´ 105 cells) into the right femoral
rectus muscle was compared with a control group of mice injected
with physiological saline into the same site.
Measurement of body wasting
Body weight and tumour volume were measured once or twice a
week. The volume of the tumour grown in the s.c. transplantation
site was estimated by using the following equation, ab2/2, where a
and  b are tumour length and width, respectively. The tumour
weight grown in the liver was estimated by subtracting the average
weight of the tumour-free livers of sham-operated mice from that
of the tumour-transplanted liver. The carcass weight, the differ-
ence in weight between the whole body and tumour tissue, was
also calculated. To determine the extent of the adipose tissue
wasting, we measured the weight of the left epididymal adipose
tissues.
Assays
Blood samples were collected from the heart of chloroform-anaes-
thetized mice via cardiac puncture. Tumour tissues and the liver
were homogenized in phosphate buffered saline (pH 7.4) on ice
with a potter homogenizer and then centrifuged at 5000 g for
10 min. To determine the concentration of substances in serum or
plasma and tissues to be tested, the following methods and
reagents were used: an enzyme reaction method with mutarotase
and glucose oxidase for measuring glucose by the Glucose CII test
(Wako, Osaka, Japan); a colour-chelate method with o-cresol
phthalein complexone for measuring calcium by the Calcium C-
Test (Wako, Osaka, Japan) (Gitelman, 1967); enzyme-linked
immunosorbent assay (ELISA) systems for measuring IL-6, TNF-
a (Endogen, Boston, MA, USA) and IL-1a (Genzyme, Boston,
MA, USA).
Northern blotting
RNA was extracted from tumour tissues with TRIZOL reagent
(GIBCO BRL, Life Technologies, Inc., Rockville, MD, USA).
Twenty micrograms of total RNA were electrophoresed in 1%
agarose gels containing formaldehyde and were transferred
to Hybond-N+ membranes (Amersham International plc,
Buckinghamshire, UK). Hybridization was performed at 42°C for
16 h with a 2 ´ 106 cpm/ml 32P-radiolabelled probe prepared from
the C-terminal region, which includes the 3´-untranslated region
(nucleotide residues 532–992) of the mouse IL-6 cDNA. Then the
membrane was washed in 2 ´ SSC/0.1% sodium dodecyl sulphate
at 42°C for 2 h. Autoradiograms of the membrane were obtained
using a BAS-1500 Bioimaging Analyzer (Fuji Film, Japan).
Histology
Tissue specimens were obtained from tumours grown in the
subcutis and in the liver. The tumour tissues were cut into thin
slices and immersed in a Tissue-Tek OCT, for 20 min. The tumour
slices were then frozen on dry ice, embedding in Tissue-Tek OCT
and kept frozen at –80°C. Other slices of tumour tissues were fixed
immediately with 10% neutral-buffered formalin in phosphate-
buffered saline (PBS). The fixed tissues were dehydrated sequen-
tially in ethanol and xylene, and then embedded in paraffin blocks.
For haematoxylin–eosin staining, 2-mm-thick paraffin sections of
tissues were placed on slides, deparaffinized with xylene, washed
with ethanol, and then transferred to distilled water. The hydrated
sections were then stained with haematoxylin and eosin solutions.
For immunohistochemical staining, 4-mm cryostat sections of
the frozen embedded tissues were placed on slides and fixed for
10 min in 4°C acetone and then transferred to 0.1 M PBS (pH 7.4).
The fixed slides were immunostained according to the ABC proce-
dure (Hsu et al, 1981). Briefly, the slides were incubated with 3%
skim milk containing PBS for 30 min at room temperature, with
the rat monoclonal antibody to murine IL-6 (MM-600C, Endogen,
MA, USA) overnight at 4°C, and with biotinylated rabbit anti-rat
IgG antibody (BA-4001, Vector Laboratories, CA, USA) for
30 min at room temperature. This was followed by incubation in
avidin–biotinylated peroxidase (PK-6100, Vector Laboratories,
CA, USA) for 30 min at room temperature, and then they were
developed in a mixture of diaminobenzidine and hydrogen
peroxide for 5 min at room temperature, which resulted in a brown
reaction product.
Statistics
Differences in tumour size, tissue weight and concentrations of
substances were compared by using the Mann–Whitney U-test.
Differences were considered to be significant when the probability
value was less than 0.05 (P < 0.05).
RESULTS
Tumour-inoculation site-dependent cachexia
expression
Mice bearing colon 26 at the s.c. inoculation site lost body weight
starting around day 10 after tumour inoculation (Figure 1). They
were also partially immobile, and experienced asthenia and pilo-
erection. On day 17, even when the tumour size was only 0.36 g,
which was about 1.9% of carcass weight, significant decreases in
carcass weight and adipose tissue, hypoglycaemia, and hypercal-
caemia were observed (Table 1). The difference in the carcass
weight between the tumour-bearing mice and the age-matched
controls reached 8.7 g, and the adipose tissue weight of the
cachectic mice was 69 ± 43 mg compared with 367 ± 41 mg for the
control mice. In contrast, mice bearing the same colon 26 inocu-
lated into the liver did not show any significant change in carcass
weight and adipose tissue weight on day 17, even though the
tumour weight was 1.61 g, which was about 6.6% of carcass
weight. Nevertheless, hypoglycaemia and mild hypercalcaemia
were observed (Table 1). The colon 26 grown in the liver (up to
day 17) was removed, cut into small pieces, and re-inoculated s.c.
with a trocar to investigate whether it had lost its ability to cause
cachexia. Figure 2 and Table 1 show that its ability to cause
cachexia remained intact and was the same as that of the original
colon 26. Its growth pattern was also the same and it caused
progressive weight loss starting around day 10 after tumour inocu-
lation (Figure 2). It also caused substantial adipose tissue weight
Cachexia depends on tumour inoculation site 765
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loss even when the tumour size was small (3.3% of carcass weight)
(Table 1).
Similar changes in carcass weight and adipose tissue weight
were observed in mice bearing the colon 26 in their muscle (Table
1). In these mice, the tumour grew faster than did the one inocu-
lated s.c. On day 13, when the mean tumour size was 0.67 g (3.5%
of carcass weight), their carcass weight had decreased to 19.1 g,
which was equivalent to 67% of that of the age-matched controls.
Colon 26 causes cachexia producing IL-6
IL-6 is reported to be a cachexia mediator in the colon 26 model
(Strassmann et al, 1992a; Fujimoto-Ouchi et al, 1995). We there-
fore investigated whether the colon 26 cells grown in the subcutis
were producing IL-6. As Table 2 shows, a significant amount of IL-
6 was detected in the colon 26 grown in the subcutis, whereas only
slight amounts were found in the same tumour grown in the liver. In
addition, higher serum IL-6 levels were detected in mice bearing
the tumour grown in the subcutis than in the liver. The difference in
the IL-6 expression levels was also observed when IL-6 mRNA
levels in the colon 26 grown in the liver and in the subcutis were
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Figure 1 Time-courses of changes in tumour volume and body weight of
mice bearing colon 26. Groups of seven mice were inoculated on day 0 with
colon 26 cells subcutaneously (l) or in the liver (n). Body weight and tumour
volume were measured periodically. Body weight of age- and sex-matched
control mice were monitored; normal mice (n = 6; l l) as the controls for those
bearing the tumour in the subcutis and sham-operated mice for those bearing
tumour in the liver (n = 6; n n). Each value represents the mean ± SD
Table 1 Physiological changes observed in mice bearing the colon 26 carcinoma
Inoculation site Muscle Subcutis Liver Subcutis (retransplanted)
Days after inoculation 13 17 17 21
Number of mice Tumour-free Tumour-bearing Tumour-free Tumour-bearing Tumour-free Tumour-bearing Tumor-free  Tumor-bearing
5467776 7
Parameters
Tumour weight (g) – 0.67 ± 0.16 – 0.36 ± 0.05 – 1.61 ± 0.85 – 0.59 ± 0.19
Carcass weight (g) 28.4 ± 1.0 19.1 ± 1.6b 27.7 ± 1.4 19.0 ± 1.6a 25.4 ± 1.3 24.5 ± 2.1 26.2 ± 1.6 17.8 ± 2.1a
Adipose tissue weight (mg) 289 ± 30 31 ± 12b 367 ± 41 69 ± 43a 339 ± 70 315 ± 89 252 ± 60 33 ± 39a
Serum glucose (mg/dl) 158 ± 25 63 ± 31b 183 ± 22 73 ± 33b 195 ± 27 100 ± 19b 178 ± 8 103 ± 3b
Serum calcium (mg/dl) 7.5 ± 0.9 17.8 ± 3.2b 8.6 ± 1.1 15.5 ± 0.7b 8.7 ± 1.3 11.2 ± 4.1 8.3 ± 0.7 13.0 ± 0.7b
Colon 26 cells (5 ´ 105) or pieces of colon 26 tumour tissue grown in the liver were inoculated into the subcutis. The mice were killed on the days indicated in
the Table, and tumours and epididymal adipose tissues were weighted. Carcass weight was calculated by subtracting the tumour weight from the whole body
weight. Each value represents the mean ± SD. a, bsignificantly different from the value obtained in tumour-free mice (P < 0.05, 0.01).
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Figure 2 Time-courses of changes in tumour volume and body weight of
mice re-transplanted subcutaneously with colon 26 tumour grown in the liver.
Seven mice were subcutaneously transplanted on day 0 with the tumour
tissues (l). Body weight and tumour volume were measured periodically.
Body weight of age- and sex-matched normal mice (n = 6) were also
monitored (l l). Each value represents the mean ± SDCachexia depends on tumour inoculation site767
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compared in a Northern blot analysis (Figure 3). The mRNA
expression level was high in the tumour grown in the subcutis,
whereas it was very low in that grown in the live r. Conversel y,
protein expression of the other cytokines so far tested in the tumour
tissues, IL- 1aand TNF -a, did not correlate with the cachexia
expression, and these cytokines were not detected in the serum.
Difference in histology of colon 26 grown in different
inoculation sites
Figure 4 shows colon 26 tissues stained with haematoxylin and
eosin solutions. The tumour tissues grown in the subcutis were
characterized by many polygonal tumour cells resulting in
extended intercellular space and condensed chromatin, and
showing high vascular densit y. In contrast, histological character-
istics of the same tumour grown in the liver di ffered from those of
the s.c. tumour; all of the tumour cells were spindle-shaped with
light nuclei and existed in close contact with one anothe r. Figure 5
shows colon 26 tissues stained with anti-mouse IL-6 antibod y. In
the tumour tissues grown in the subcutis, most of the vital tumour
cells were stained, particularly foci comprising several tumour
cells; howeve r, the tumour tissues grown in the liver were stained
only very slightly (data not shown).
DISCUSSION
Cachexia is one of the major obstacles in cancer therap y, and an
appropriate treatment modality is necessary to counteract it.
Table 2Cytokine levels in mice bearing the colon 26 carcinoma
Tumour-bearing mice
Inoculation site Tumour-free mice Subcutis Liver Subcutis (retransplantation)
Number of mice 6 7 7 7
Serum IL-6 (ng/ml) < 0.02 1.64 ±0.71 0.26 ±0.31a,b 1.03 ±0.63
IL-6 in the tumour tissue (ng/g) – 147 ±69 8.8 ±5.1b 142 ±119
IL-6 in the liver tissue (ng/g) 0.23 ±0.06 0.17 ±0.09 NE NE
IL-1ain the tumour tissue (ng/g) – 0.28 ±0.22 0.82 ±0.12 0.50 ±0.44
TNF-ain the tumour tissue (ng/g) – 31.2 ±13.9 20.2 ±3.5 16.1 ±3.5
The levels of cytokines in sera and tissues from the same mice used in the experiment shown in Table 1 were determined by ELISA. Each value represents the
mean ±SD. NE: Not examined, aIL-6 was not detected in three out of seven mice (< 0.02ng/ml). bsignificantly different from the value obtained in mice bearing
tumour subcutaneously (P < 0.01).
IL-6
b-actin
Subcutis Liver
Figure 3Suppression of IL-6 mRNA expression in colon 26 tumour cells
growing in the liver. Twenty micrograms of total RNAs, isolated from tumour
tissue inoculated and grown in the subcutis or in the liver, were run on a
denaturing agarose gel, and IL-6 mRNA was detected by Northern blot
hybridization as a transcript of about 1.1kb
AB
Figure 4Photomicrographs of sections of colon 26 tumour tissues. Formalin-fixed and paraffin-embedded tumour tissues were sectioned and stained with
hematoxylin and eosin solution. (A) Colon 26 tumour tissue grown in the subcutis. (B) Colon 26 tumour tissue grown in the liver. Original magnification: ´100.
Bars = 100m m768 T Matsumoto et al
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However, the mechanisms that cause cachexia have not yet been
fully investigated. We have shown that murine colon 26 carci-
noma is an appropriate model for investigating the mechanisms
that induce cachexia (Tanaka et al, 1990; Eda et al, 1991;
Fujimoto-Ouchi et al, 1995). The present study demonstrated with
this model that a cachexia-inducing phenotype is expressed when
the tumour is growing in a particular tissue environment. The
colon 26 inoculated s.c. causes extensive wasting of body weight
and other abnormalities associated with cachexia even when the
tumour size is small (Tanaka et al, 1990; Strassman et al, 1992a).
The colon 26 grown in muscle was also able to cause cachexia.
Interestingly, the same colon 26 did not cause body weight loss
when inoculated into the liver. The colon 26 grown in the liver,
however, again caused cachexia when it was removed and re-
inoculated s.c.; this is similar to what was observed with the
tumour when it was initially inoculated s.c. Because we used a
freshly cloned cell line in the present study, the inoculation-site-
dependent expression of cachexia would not be due to a clonal
selection of the tumour cells losing their cachexia-inducing capa-
bility. The capability should be expressed by particular stimuli in
the tumour environment.
Cachexia is known to be caused by mediators, and it has been
reported that several cytokines, such as TNF-a, IL-1a, IL-6 and
other factors, would be such mediators. Strassman et al (1992a)
reported that an anti-IL-6 antibody protected mice from becoming
cachectic in the colon 26 model; this would suggest that IL-6 is
involved in cachexia induction. We confirmed the involvement of
IL-6 in the colon 26 model, although it did not appear to be the
sole mediator (Fujimoto-Ouchi et al, 1995). The present study
demonstrated that the colon 26 grown in the subcutis expressed
IL-6 mRNA and protein and caused cachexia, whereas the same
tumour grown in the liver expressed IL-6 only slightly and did not
cause cachexia. In contrast, neither IL-1a nor TNF-a production
in the tumour correlated with the cachexia induction. Thus, colon
26 exposed to only particular stimuli in the subcutis would trigger
IL-6 gene expression. The possibility, however, that an accelerated
rate of IL-6 mRNA degradation in the liver results in no expres-
sion of cachexia phenotype cannot be excluded.
We do not yet know how IL-6 gene expression and protein
levels are regulated in the colon 26 carcinoma. Factors in the
tumour tissues may modulate the IL-6 expression. TNF-a and IL-
1a are reported to up-regulate IL-6 production (Fiers, 1991;
Strassmann et al, 1992b, 1993). It is not likely that these factors
alone regulate the IL-6 expression in the colon 26, however,
because levels of these factors did not correlate with cachexia
induction. Steinkassere et al (1992) reported that a secreted form
of IL-1 receptor antagonist, which suppresses IL-1 production
(Arend et al, 1985), is expressed in the human liver. Therefore, an
IL-1a receptor antagonist produced and secreted by host cells
surrounding the tumour cells may down-regulate IL-6 production
in the colon 26 growing in the liver. In fact, Strassmann et al
(1993) reported that intratumoral injection of IL-1 receptor antag-
onist alleviated colon 26-induced cachexia.
Phenotypic expression of tumours is often affected by environ-
mental factors. Productions of lectins in colon 26 (Vidal-
Vanaclocha et al, 1991) and matrix metaloproteinase in colon
cancer xenografts (Nakajima et al, 1990) were reported to be
tumour inoculation-site-dependent. The present study showed that
cachexia expression in colon 26 was indeed such a case.
Differences in tumour environments may lead to the different
phenotypic expressions, such as ability of colon 26 to cause
tumour cachexia in the subcutis as well as in the muscle, but not in
the liver. Factors that modulate expression of cachectic phenotypes
of colon 26 should exist to a different extent between the tumours
grown in the subcutis and in the liver. This is likely since the histo-
logical characteristics of colon 26 grown in the different inocula-
tion sites are quite different. There were dispersed foci of tumour
cells expressing high IL-6 immunoreactivity only in the tumour
tissue growing in the subcutis. In addition, host cells, including
macrophage-like cells, were infiltrated into the tumour. In contrast,
fibroblast-like cells existed in the tumour grown in the liver.
Strassmann et al (1992b) suggested that host macrophages inter-
acting with colon 26 tumour cells produce IL-1, which in turn up-
regulates the production of IL-6 in the tumour cells. The
mechanism causing cachexia by colon 26 tumours in the particular
environment remains to be clarified.
AB
Figure 5 Immuno-histochemical staining of colon 26 tumour tissue grown in the subcutis for IL-6. Tumour tissue sections were immunoperoxidase-stained with
monoclonal antibody to murine IL-6. The sections were counterstained with haematoxylin. Original magnifications: (A) ´ 20; (B) ´ 100. Bar = 100 mmCachexia depends on tumour inoculation site 769
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